[NCI CIRB] S1931: PHASE III TRIAL OF IMMUNOTHERAPY-BASED COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)
The purpose of this study is to compare any good and bad effects of performing surgery to reduce the amount of cancer in the body. We wish to understand the effects of starting drug therapy followed by possible surgery and then more drug therapy. We are also doing this study because we want to find out if this approach is better or worse than the usual approach for kidney cancer.
Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma (RCC)
Histologically proven diagnosis of clear cell or non-clear cell renal cell carcinoma
Primary tumor in place.
Imaging showing evidence of metastatic disease.
≥ 18 years old
Must have both kidneys (transplanted kidney not acceptable).
18 - 99
Healthy Volunteers Needed
Duration of Participation
Knight Information Line - email@example.com or 503-494-1080